CALR and myeloproliferative neoplasm: It is notable that even so-called “triple-negative” MPN patients who lack a driver mutation in JAK2, CALR, or MPL show activated JAK2 signaling, highlighting the significance of the JAK2 signaling network for MPN pathogenesis [36].